Business Context and Reporting Period
Company: Ocular Therapeutix, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 14, 2024
Reporting Period: Quarter ended September 30, 2024
Context: This filing serves to announce the company's financial results for the third quarter of 2024. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover page and index for the Form 8-K. It references the announcement of financial results but does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These figures are located in the attached Exhibit 99.1 (Press Release), which is not included in the input text.
Material Changes
The filing text does not provide specific details on material changes versus the prior comparable period. It only confirms that results for the quarter ended September 30, 2024, have been announced.
Guidance, Outlook, and Risks
The text does not include management commentary, forward-looking guidance, specific risk factors, or details on contingencies. It notes that the information is furnished to comply with Item 2.02 and is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 14, 2024) for actual revenue, net loss, and cash position figures.
- Verify the specific details of the "Results of Operations" referenced in Item 2.02, as they are not present in the 8-K cover text.
- Check for any updated guidance or clinical trial milestones mentioned in the full press release.
- Confirm the company's status as an emerging growth company (indicated as checked in the filing) and its implications for financial reporting.